Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Go back to Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death| Pfizer Inc. (NYSE: PFE) | Delayed: 28.02 -0.28 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.30 | 52 Week High | $37.39 | |||
| Open | $27.97 | 52 Week Low | $28.25 | |||
| Day High | $28.18 | P/E | 16.98 | |||
| Day Low | $27.83 | EPS | $1.65 | |||
| Volume | 31,198,086 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.02 -0.28 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.30 | 52 Week High | $37.39 | |||
| Open | $27.97 | 52 Week Low | $28.25 | |||
| Day High | $28.18 | P/E | 16.98 | |||
| Day Low | $27.83 | EPS | $1.65 | |||
| Volume | 31,198,086 | |||||
